If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
